Filtered By:
Education: Study
Therapy: Stem Cell Therapy
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 1233 results found since Jan 2013.
Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Media News - July 13, 2023 Category: Pharmaceuticals Source Type: news
Identification of key biomarkers in ischemic stroke: single-cell sequencing and weighted co-expression network analysis
CONCLUSIONS: Our study provides a reference for the study of pathogenesis and key targets of ischemic stroke.PMID:37418282 | DOI:10.18632/aging.204855
Source: Aging - July 7, 2023 Category: Biomedical Science Authors: Jiali Tao Xiaochen Xie Man Luo Qingsong Sun Source Type: research
Neuroprotection of Stem Cells Against Ischemic Brain Injury: From Bench to Clinic
AbstractNeurological injuries can have numerous debilitating effects on functional status including sensorimotor deficits, cognitive impairment, and behavioral symptoms. Despite the disease burden, treatment options remain limited. Current pharmacological interventions are targeted at symptom management but are ineffective in reversing ischemic brain damage. Stem cell therapy for ischemic brain injury has shown promising preclinical and clinical results and has attracted attention as a potential therapeutic option. Various stem cell sources (embryonic, mesenchymal/bone marrow, and neural stem cells) have been investigat...
Source: Translational Stroke Research - July 7, 2023 Category: Neurology Source Type: research
Efficacy of redox nanoparticles for improving survival of transplanted cells in a mouse model of ischemic stroke
In this study, we tested the protective efficacy of these redox nanoparticles in cell culture and a mouse model of ischemic stroke. Induced human dental pulp stem cells were subjected to oxygen –glucose deprivation and reoxygenation to recapitulate ischemia and reperfusion in the penumbra surrounding a cerebral infarct. Cell viability using WST-8 assay, apoptosis using TUNEL, free radicals using MitoSOX, and inflammatory cytokines using ELISA kit were measured in the presence and absence of redox nanoparticles after oxygen–glucose deprivation and reoxygenation. The scavenging activity of redox nanoparticles against rea...
Source: Human Cell - July 7, 2023 Category: Cytology Source Type: research
Neuroprotection of Stem Cells Against Ischemic Brain Injury: From Bench to Clinic
Transl Stroke Res. 2023 Jul 7. doi: 10.1007/s12975-023-01163-3. Online ahead of print.ABSTRACTNeurological injuries can have numerous debilitating effects on functional status including sensorimotor deficits, cognitive impairment, and behavioral symptoms. Despite the disease burden, treatment options remain limited. Current pharmacological interventions are targeted at symptom management but are ineffective in reversing ischemic brain damage. Stem cell therapy for ischemic brain injury has shown promising preclinical and clinical results and has attracted attention as a potential therapeutic option. Various stem cell sourc...
Source: Cell Research - July 6, 2023 Category: Cytology Authors: Xiao Liu Xiaofeng Jia Source Type: research
Transmembrane Stem Factor Nanodiscs Enhanced Revascularization in a Hind Limb Ischemia Model in Diabetic, Hyperlipidemic Rabbits
Res Sq. 2023 Jun 16:rs.3.rs-2997323. doi: 10.21203/rs.3.rs-2997323/v1. Preprint.ABSTRACTTherapies to revascularize ischemic tissue have long been a goal for the treatment of vascular disease and other disorders. Therapies using stem cell factor (SCF), also known as a c-Kit ligand, had great promise for treating ischemia for myocardial infarct and stroke, however clinical development for SCF was stopped due to toxic side effects including mast cell activation in patients. We recently developed a novel therapy using a transmembrane form of SCF (tmSCF) delivered in lipid nanodiscs. In previous studies, we demonstrated tmSCF n...
Source: Cell Research - July 3, 2023 Category: Cytology Authors: Eri Takematsu Miles Massidda Gretchen Howe Julia Goldman Patricia Felli Lei Mei Gregory Callahan Andrew Sligar Richard Smalling Aaron Baker Source Type: research
MiR-199a-5p enhances neuronal differentiation of neural stem cells and promotes neurogenesis by targeting Cav-1 after cerebral ischemia
CONCLUSION: MiR-199a-5p may target and inhibit Cav-1 to enhance neurogenesis and thus promote functional recovery after cerebral ischemia. These findings indicate that miR-199a-5p is a promising target for the treatment of ischemic stroke.PMID:37349971 | DOI:10.1111/cns.14323
Source: CNS Neuroscience and Therapeutics - June 23, 2023 Category: Neuroscience Authors: Hua-Qian Jin Wei-Feng Jiang Xin-Tian Zheng Lin Li Yan Fang Yan Yang Xiao-Wei Hu Li-Sheng Chu Source Type: research
Functional reconstruction of the impaired cortex and motor function by hMGEOs transplantation in stroke
Biochem Biophys Res Commun. 2023 Jun 3;671:87-95. doi: 10.1016/j.bbrc.2023.06.010. Online ahead of print.ABSTRACTStroke is the leading cause of death and long-term disability worldwide. But treatments are not available to promote functional recovery, and efficient therapies need to be investigated. Stem cell-based therapies hold great promise as potential technologies to restore function in brain disorders. Loss of GABAergic interneurons after stroke may result in sensorimotor defects. Here, by transplanting human brain organoids resembling the MGE domain (human MGE organoids, hMGEOs) derived from human induced pluripotent...
Source: Cell Research - June 10, 2023 Category: Cytology Authors: Shi-Ying Cao Meng-Dan Tao Shu-Ning Lou Di Yang Yu-Hui Lin Hai-Yin Wu Lei Chang Chun-Xia Luo Yun Xu Yan Liu Dong-Ya Zhu Source Type: research
Temporal patterns and distribution of pyroptosis-related molecules and effects of human mesenchymal stem cells on pyroptosis following cerebral ischemia/reperfusion in rats
Pyroptosis is a new type of programmed cell death that has a strong proinflammatory effect. The present study investigated the dynamic changes of pyroptosis-related molecules and the effect of mesenchymal stem cells (MSCs) on pyroptosis following cerebral ischemia/reperfusion (I/R).
Source: Journal of Stroke and Cerebrovascular Diseases - May 31, 2023 Category: Neurology Authors: Kuang Pan, Qingxia Peng, Zejia Huang, Zhaofei Dong, Weijye Lin, Yidong Wang Source Type: research
Bone Marrow Mesenchymal Stem Cell-Derived Dermcidin-Containing Migrasomes enhance LC3-Associated Phagocytosis of Pulmonary Macrophages and Protect against Post-Stroke Pneumonia
Adv Sci (Weinh). 2023 May 28:e2206432. doi: 10.1002/advs.202206432. Online ahead of print.ABSTRACTPneumonia is one of the leading causes of death in patients with acute ischemic stroke (AIS). Antibiotics fail to improve prognosis of patients with post-stroke pneumonia, albeit suppressing infection, due to adverse impacts on the immune system. The current study reports that bone marrow mesenchymal stem cells (BM-MSC) downregulate bacterial load in the lungs of stroke mice models. RNA-sequencing of the lung from BM-MSC-treated stroke models indicates that BM-MSC modulates pulmonary macrophage activities after cerebral ischem...
Source: Adv Data - May 28, 2023 Category: Epidemiology Authors: Tiemei Li Xiaotao Su Pinglan Lu Xinmei Kang Mengyan Hu Chunyi Li Shisi Wang Danli Lu Shishi Shen Huipeng Huang Yuxin Liu Xiaohui Deng Wei Cai Lei Wei Zhengqi Lu Source Type: research
